Skip to main content
. Author manuscript; available in PMC: 2010 Jun 1.
Published in final edited form as: J Clin Pharmacol. 2009 Jun;49(6):650–660. doi: 10.1177/0091270009335001

Table 3.

Treatment-related adverse events occurring > 10% for continuous dosing (n=15)

Adverse Events Grade 1 Grade 2 Grade 3 Grade 4
Blood/Bone Marrow
  Anemia 1
  Neutropenia 1 3 2
Cardiovascular
  Hypotension 2 1
  Thrombosis 2
Constitutional symptoms
  Fatigue 4 1
Dermatology/skin
   Rash/desquamation 4
   Pruritus 5 1
Gastrointestinal
  Constipation 2 1
  Diarrhea 4
  Flatulence 3
  Nausea 4
Metabolic/Laboratory
  SGPT 2
Neurology
  Dizziness 3 1
  Neuropathic Sensory 4
Pulmonary
  Pleural effusion 2